Summary
A new daily pill called orforglipron has shown potential for significant weight loss in people with obesity. In a study with over 3,000 people, the pill helped reduce body weight by up to 11.2% over 72 weeks without meal or water timing restrictions, which differ from other similar weight loss drugs. This study was presented at a major diabetes conference and supports the development of oral medications as an alternative to injections.
Key Facts
- Orforglipron is a GLP-1 drug taken as a daily pill for weight loss in people with obesity.
- A 72-week study included around 3,000 adults and showed weight losses of up to 11.2%, depending on the dose.
- The study was conducted in multiple countries and sponsored by Eli Lilly.
- Participants taking the highest dose of orforglipron experienced weight loss of 10% or more in 54.6% of cases.
- The drug can be taken without restrictions on food or water intake, unlike some other similar medications.
- Common side effects include mild to moderate gastrointestinal issues.
- Orforglipron works in a similar way to other drugs like semaglutide, which are usually given through injections.
